Dr Nyjon K Eccles BSc MBBS MRCP PhD
For nearly a century, a puzzling question has lingered at the heart of cancer biology: Why do cancer cells, even in the presence of ample oxygen, abandon the efficient energy-producing process of their mitochondria and revert to a primitive, wasteful form of metabolism known as aerobic glycolysis?
This phenomenon, first observed by Otto Warburg in the 1930s and now visibly confirmed by PET scans, is a hallmark of most cancers. Yet, for decades, it was largely dismissed as a mere side effect of the disease—a consequence of permanently damaged mitochondria. The real engines of cancer, the thinking went, were the genetic mutations driving uncontrolled growth. The metabolic shift was just along for the ride.
But what if this metabolic shift isn’t a result of cancer, but a fundamental cause of its most deadly traits? And what if the mitochondria in cancer cells aren’t permanently broken, but are instead deliberately and reversibly suppressed?
The Metabolic-Electrical Remodeling of Cancer
Recent research has rekindled the metabolic theory of cancer, painting a more sophisticated picture. It’s proposed that as cells become cancerous in a low-oxygen (hypoxic) environment, they adapt by relying on glycolysis. This adaptation, however, comes with a sinister bonus: it suppresses apoptosis, the programmed cell death that is our body’s primary defense against rogue cells.
This isn’t just about energy. The metabolic and apoptotic pathways are deeply intertwined within the mitochondria. By shifting to glycolysis, cancer cells rewire their entire biology to become “addicted” to a state that is both highly proliferative and resistant to death.
This “metabolic-electrical remodeling” has several key features:
- Hyperpolarized Mitochondria: Unlike normal cells, cancer cells often have mitochondria with an abnormally high electrical charge. This hyperpolarized state makes them resistant to opening the “suicide gates” that release pro-apoptotic factors.
- The PDH Gatekeeper: A critical mitochondrial enzyme, Pyruvate Dehydrogenase (PDH), acts as a gatekeeper. It decides whether pyruvate (the end-product of glycolysis) will be used for mitochondrial energy production or be shunted away to become lactate. In cancer, PDH is actively inhibited by another enzyme, PDK (Pyruvate Dehydrogenase Kinase).
- Suppressed Potassium Channels: This metabolic remodeling extends beyond the mitochondria. Cancer cells often downregulate specific potassium channels on their surface. This leads to an increase in intracellular potassium, which exerts a powerful tonic inhibition on the enzymes (caspases) that execute cell death.
The result is a perfect storm: a cell that is metabolically primed for growth, electrically resistant to death, and stubbornly resistant to treatments designed to trigger apoptosis.
DCA Research: Suggests metabolic disruption in cancer cells is NOT IRREVERSIBLE.
If this rewiring is reversible, could we “normalize” cancer cells and make them susceptible to death again? This is where a simple, decades-old drug called Dichloroacetate (DCA) enters the story.
DCA is a well-characterized inhibitor of PDK (Pyruvate Dehydrogenase Kinase). Its mechanism is elegantly straightforward:
- It Reverses the Metabolic Shift: By inhibiting PDK, DCA “un-blocks” PDH. This forces pyruvate back into the mitochondria, restarting oxidative phosphorylation and reducing lactate production.
- It Depolarizes Mitochondria: The reactivation of mitochondrial metabolism increases the production of Reactive Oxygen Species (ROS). Over time, this ROS damages the electron transport chain, leading to a decrease in the mitochondrial membrane potential. This depolarization opens the door for reactivation of apoptosis.
- It Restores Potassium Channels: The increase in mitochondrial ROS and other signalling changes reactivates the expression and function of the suppressed potassium channels. The resulting efflux of potassium from the cell lowers intracellular potassium levels, releasing the brake on the cell’s death machinery.
In essence, DCA forces the cancer cell to behave like a normal cell. And when a cancer cell is forced to act normally, it can no longer survive. Crucially, these effects appear to be selective for cancer cells, sparing healthy ones.
The Future of Metabolic Cancer Therapy
The story of DCA and mitochondrial dysfunction represents a paradigm shift in oncology. It suggests that:
- The Warburg Effect is reversible, not a permanent state.
- Metabolic modulators could be powerful allies, either alone or as “apoptosis sensitizers” to enhance the effect of traditional chemotherapy.
- Targeting a fundamental property of cancer cells offers the promise of efficacy with high selectivity and low toxicity.
While DCA itself is not yet a standard cancer treatment and requires more clinical study, it has served as a powerful proof-of-concept. It has opened our eyes to the “metabolic-electrical remodeling” of cancer and unveiled a new class of targets, from PDK to mitochondrial membrane potential and potassium channels.
The journey from Warburg’s observation to modern mitochondrial medicine has been long and contentious. But it has brought us to a promising frontier: one where we no longer see cancer cells as just genetically broken machines, but as metabolically rewired entities that can be forced to self-destruct by reminding them of their healthy origins.
References
- Seyfried, T. N. (2012). Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. John Wiley & Sons.
- This is Seyfried’s seminal book, providing the comprehensive foundation for his theory, complete with extensive experimental evidence and critical analysis of the Somatic Mutation Theory.
- Seyfried, T. N., & Shelton, L. M. (2010). Cancer as a metabolic disease. Nutrition & Metabolism, 7(1), 7.
- A key review article that succinctly summarizes the core principles of the MMT and the evidence from nuclear transfer and other experiments.
- Seyfried, T. N., Marsh, J., Shelton, L. M., Huysentruyt, L. C., & Mukherjee, P. (2012). Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Research, 100(3), 310-326.
- This paper discusses the practical application of the ketogenic diet as a therapeutic strategy, particularly for aggressive cancers like glioblastoma.
- Seyfried, T. N., Flores, R. E., Poff, A. M., & D’Agostino, D. P. (2014). Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis, 35(3), 515-527.
- A paper exploring the implications of the metabolic theory for developing new treatment protocols and combining metabolic therapy with traditional approaches.
- Weinberg, F., et al. (2010). Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proceedings of the National Academy of Sciences, 107(19), 8788-8793.
- While not by Seyfried, this paper is an example of growing evidence in the literature that even cancers driven by potent oncogenes like Kras are dependent on mitochondrial dysfunction and reactive oxygen species (ROS), supporting the metabolic link.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Dichloroacetate (DCA) is not an approved treatment for cancer in many countries, and its use should only be considered under the strict supervision of a qualified physician within a clinical trial setting.
What Are You Waiting For...
Ask a Question or book a Consultation
If you are interested in learning more about our targeted Metabolic Support Plan fill in the contact form or send your inquiry via email.